TEL AVIV—Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), recently sold a substantial block of the company's ordinary shares. The sale comes as InvestingPro analysis shows the stock trading below its Fair Value, with a market capitalization of $18.9 billion. According to a filing with the Securities and Exchange Commission, Sabag divested 177,626 shares on February 12, 2025. The shares were sold at a weighted average price of $16.2508, totaling approximately $2.89 million.
The transactions were part of multiple sales, with prices ranging from $16.21 to $16.335 per share. Following this sale, Sabag holds 204,964 shares in the company. The ordinary shares may be represented by American Depositary Shares, each equivalent to one ordinary share.
In other recent news, Axsome Therapeutics (NASDAQ:AXSM), Inc. has settled a patent litigation with Teva Pharmaceuticals, extending its exclusivity on the drug AUVELITY® till September 2038 or March 2039, depending on FDA approval and standard conditions. Truist Securities analyst Joon Lee maintained a Buy rating on the company following the settlement.
In related news, Bank of America (NYSE:BAC) Securities has revised its financial model for Teva Pharmaceutical Industries Ltd, resulting in a lowered price target from $26.00 to $23.00, while maintaining a Buy rating. The firm anticipates an increase in operating expenses between 2026 and 2029, primarily to support investments in the TL1a clinical program.
Meanwhile, Teva Pharmaceutical Industries Ltd reported fourth-quarter earnings exceeding analyst estimates, with an adjusted earnings per share of $0.71 and revenue of $4.23 billion. However, the company's 2025 outlook fell short of Wall Street forecasts, projecting earnings per share of $2.35-$2.65 and revenue of $16.8-17.4 billion. These are the most recent developments for both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.